Fortunately, the FDA has approved antipsychotic treatments that help manage these destructive symptoms, and more are in ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

There are many mechanisms at work here, but the blood sugar increase is probably secondary to the weight gain, rather than ...

Antipsychotics are the best defense against relapse in schizophrenia, even though that protection often comes at the expense ...

A new report that lists what it calls the best nursing homes in the US finds that top-rated facilities continuously excel ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Bristol Myers Squibb's (BMY) new schizophrenia drug, Cobenfy, improves symptoms with a well-tolerated safety profile in two ...

Resulting data from 9,525 participants determined that while antipsychotics as a group showed slight cognitive benefits, no individual drug demonstrated a substantial advantage over placebo.

The worldwide growing occurrences of mental health disorders are significantly boosting the antipsychotic drugs market. An estimated 21% of U.S. adults have mental illness in 2023, which is over ...